Single-Cell Transcriptomics Revealed Subtype-Specific Tumor Immune Microenvironments in Human Glioblastomas

• Published in: Frontiers in immunology 2022-05, Vol.13, p.914236-914236
• Main Authors: Xiao, Yong, Wang, Zhen, Zhao, Mengjie, Deng, Yanxiang, Yang, Mingyu, Su, Graham, Yang, Kun, Qian, Chunfa, Hu, Xinhua, Liu, Yong, Geng, Liangyuan, Xiao, Yang, Zou, Yuanjie, Tang, Xianglong, Liu, Hongyi, Xiao, Hong, Fan, Rong
• Format: Article
• Language: English
• Subjects: cellular state; glioblastoma; hypoxia; Immunology; M2-type polarization; single-cell RNA sequencing; tumor-associated macrophage
• ISSN: 1664-3224; 1664-3224
• DOI: 10.3389/fimmu.2022.914236

Human glioblastoma (GBM), the most aggressive brain tumor, comprises six major subtypes of malignant cells, giving rise to both inter-patient and intra-tumor heterogeneity. The interaction between different tumor subtypes and non-malignant cells to collectively shape a tumor microenvironment has not been systematically characterized. Herein, we sampled the cellular milieu of surgically resected primary tumors from 7 GBM patients using single-cell transcriptome sequencing. A lineage relationship analysis revealed that a neural-progenitor-2-like (NPC2-like) state with high metabolic activity was associated with the tumor cells of origin. Mesenchymal-1-like (MES1-like) and mesenchymal-2-like (MES2-like) tumor cells correlated strongly with immune infiltration and chronic hypoxia niche responses. We identified four subsets of tumor-associated macrophages/microglia (TAMs), among which TAM-1 co-opted both acute and chronic hypoxia-response signatures, implicated in tumor angiogenesis, invasion, and poor prognosis. MES-like GBM cells expressed the highest number of M2-promoting ligands compared to other cellular states while all six states were associated with TAM M2-type polarization and immunosuppression a set of 10 ligand-receptor signaling pathways. Our results provide new insights into the differential roles of GBM cell subtypes in the tumor immune microenvironment that may be deployed for patient stratification and personalized treatment.